ProQR Therapeutics N.V. announced positive Phase 1 target engagement data for AX-0810 on June 25, 2026. This data provides the first clinical validation for the company's Axiomer RNA editing platform. ProQR Therapeutics N.V. is a biotechnology company focused on developing RNA-based therapies.
